AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 11 - (NewsRx.com & NewsRx.net) -- Vical Incorporated (NASDAQ:VICL) announced that European Patent EP0737750, entitled "Expression of Exogenous Polynucleotide Sequences in a Vertebrate," has been granted to Vical.
This patent is part of a family of patents based on the company's discovery that tissues can take up polynucleotides, such as DNA or RNA, without the use of viral delivery vehicles and subsequently express the proteins encoded by the polynucleotides. Vical holds multiple issued U.S. patents covering various aspects of this key discovery.
The new patent claims medicinal compositions which contain cationic lipids and polynucleotides and which elicit an immune response against the proteins encoded by the polynucleotides. The new patent covers a range of applications of the company's core DNA delivery technology, including cationic lipid-formulated, gene-based immunotherapeutics such as Vical's clinical-stage ...